JPMorgan downgrades Sangamo to Neutral on 'growing skepticism'.
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics (SGMO) to Neutral from Overweight and lowered his price target for the shares to $11 from $35. Following the company's Q3 results, the analyst has "growing skepticism" about its lead development programs and "their potential for value creation over the foreseeable future." Visibility into the initial efficacy of the SB-525 / Hemophilia A program "continues to elude, now with indefinite timelines," Joseph tells investors in a research note. With relatively slower recruitment to date, the analyst struggles to see how SB-525 closes ground with the two later-stage competitor FVIII gene therapy programs from BioMarin (BMRN) and Spark Therapeutics (ONCE).
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 14, 2018|
|Previous Article:||Merck: Phase 3 KEYNOTE-181 trial met a primary endpoint of overall survival.|
|Next Article:||European stock markets pared some of their losses.|